Evidence map›Paper›PMID 31618653›Full record

ArticleImmunity2019

New Clones on the Block.

Nandini Acharya, Ana C Anderson

Abstract readComment
PubMed Publisher
In one paragraph

Article in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. CD8Journal for immunotherapy of cancer · 2022
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nandini AcharyaEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Ana C AndersonEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address: acanderson@bwh.harvard.edu.

Funding

Transgenic / Knock-out mouse coreP01AI073748 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BEHAR, SAMUEL M · 2008 to 2019
$17.1M
Role of Tim-3 in determining T cell immunityR01CA187975 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ANDERSON, ANA C · 2015 to 2025
$3.9M
Steroid hormone regulation of immune responsesR01CA229400 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ANDERSON, ANA C · 2018 to 2022
$1.9M
NCI NIH HHS R01 CA187975NCI NIH HHS R01 CA229400NIAID NIH HHS P01 AI073748
6 · The paper itself

Abstract

Although immune checkpoint blockade (ICB) has yielded striking clinical responses in subsets of cancer patients, the mechanism of action is still unclear. In a recent issue of Nature Medicine, Yost et al., 2019 report that the T cell clones that dominate the intra-tumoral T cell landscape after ICB are distinct from those prior to treatment, a phenomenon referred to by the authors as "clonal replacement."

Indexed as

NeoplasmsProgrammed Cell Death 1 ReceptorClone CellsHumansT-LymphocytesProgrammed Cell Death 1 Receptor

Identifiers

PMID31618653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.